Research ArticleSpecial Section on Emerging Novel Enzyme Pathways in Drug Metabolism
Phosphocholine Conjugation: An Unexpected In Vivo Conjugation Pathway Associated with Hepatitis C NS5B Inhibitors Featuring A Bicyclo[1.1.1]Pentane
Xiaoliang Zhuo, Joseph L. Cantone, Yingzi Wang, John E. Leet, Dieter M. Drexler, Kap-Sun Yeung, Xiaohua Stella Huang, Kyle J. Eastman, Kyle E. Parcella, Kathleen W. Mosure, Matthew G. Soars, John F. Kadow and Benjamin M. Johnson
Drug Metabolism and Disposition August 2016, 44 (8) 1332-1340; DOI: https://doi.org/10.1124/dmd.115.069062
Xiaoliang Zhuo
Departments of Pharmaceutical Candidate Optimization (X.Z., J.L.C., Y.W., D.M.D., X.S.H., K.W.M., M.G.S., B.M.J.), Synthesis and Analysis Technology Team (J.E.L.), and Virology Chemistry (K.-S.Y., K.J.E., K.E.P., J.F.K.), Bristol-Myers Squibb Co., Wallingford, Connecticut
Joseph L. Cantone
Departments of Pharmaceutical Candidate Optimization (X.Z., J.L.C., Y.W., D.M.D., X.S.H., K.W.M., M.G.S., B.M.J.), Synthesis and Analysis Technology Team (J.E.L.), and Virology Chemistry (K.-S.Y., K.J.E., K.E.P., J.F.K.), Bristol-Myers Squibb Co., Wallingford, Connecticut
Yingzi Wang
Departments of Pharmaceutical Candidate Optimization (X.Z., J.L.C., Y.W., D.M.D., X.S.H., K.W.M., M.G.S., B.M.J.), Synthesis and Analysis Technology Team (J.E.L.), and Virology Chemistry (K.-S.Y., K.J.E., K.E.P., J.F.K.), Bristol-Myers Squibb Co., Wallingford, Connecticut
John E. Leet
Departments of Pharmaceutical Candidate Optimization (X.Z., J.L.C., Y.W., D.M.D., X.S.H., K.W.M., M.G.S., B.M.J.), Synthesis and Analysis Technology Team (J.E.L.), and Virology Chemistry (K.-S.Y., K.J.E., K.E.P., J.F.K.), Bristol-Myers Squibb Co., Wallingford, Connecticut
Dieter M. Drexler
Departments of Pharmaceutical Candidate Optimization (X.Z., J.L.C., Y.W., D.M.D., X.S.H., K.W.M., M.G.S., B.M.J.), Synthesis and Analysis Technology Team (J.E.L.), and Virology Chemistry (K.-S.Y., K.J.E., K.E.P., J.F.K.), Bristol-Myers Squibb Co., Wallingford, Connecticut
Kap-Sun Yeung
Departments of Pharmaceutical Candidate Optimization (X.Z., J.L.C., Y.W., D.M.D., X.S.H., K.W.M., M.G.S., B.M.J.), Synthesis and Analysis Technology Team (J.E.L.), and Virology Chemistry (K.-S.Y., K.J.E., K.E.P., J.F.K.), Bristol-Myers Squibb Co., Wallingford, Connecticut
Xiaohua Stella Huang
Departments of Pharmaceutical Candidate Optimization (X.Z., J.L.C., Y.W., D.M.D., X.S.H., K.W.M., M.G.S., B.M.J.), Synthesis and Analysis Technology Team (J.E.L.), and Virology Chemistry (K.-S.Y., K.J.E., K.E.P., J.F.K.), Bristol-Myers Squibb Co., Wallingford, Connecticut
Kyle J. Eastman
Departments of Pharmaceutical Candidate Optimization (X.Z., J.L.C., Y.W., D.M.D., X.S.H., K.W.M., M.G.S., B.M.J.), Synthesis and Analysis Technology Team (J.E.L.), and Virology Chemistry (K.-S.Y., K.J.E., K.E.P., J.F.K.), Bristol-Myers Squibb Co., Wallingford, Connecticut
Kyle E. Parcella
Departments of Pharmaceutical Candidate Optimization (X.Z., J.L.C., Y.W., D.M.D., X.S.H., K.W.M., M.G.S., B.M.J.), Synthesis and Analysis Technology Team (J.E.L.), and Virology Chemistry (K.-S.Y., K.J.E., K.E.P., J.F.K.), Bristol-Myers Squibb Co., Wallingford, Connecticut
Kathleen W. Mosure
Departments of Pharmaceutical Candidate Optimization (X.Z., J.L.C., Y.W., D.M.D., X.S.H., K.W.M., M.G.S., B.M.J.), Synthesis and Analysis Technology Team (J.E.L.), and Virology Chemistry (K.-S.Y., K.J.E., K.E.P., J.F.K.), Bristol-Myers Squibb Co., Wallingford, Connecticut
Matthew G. Soars
Departments of Pharmaceutical Candidate Optimization (X.Z., J.L.C., Y.W., D.M.D., X.S.H., K.W.M., M.G.S., B.M.J.), Synthesis and Analysis Technology Team (J.E.L.), and Virology Chemistry (K.-S.Y., K.J.E., K.E.P., J.F.K.), Bristol-Myers Squibb Co., Wallingford, Connecticut
John F. Kadow
Departments of Pharmaceutical Candidate Optimization (X.Z., J.L.C., Y.W., D.M.D., X.S.H., K.W.M., M.G.S., B.M.J.), Synthesis and Analysis Technology Team (J.E.L.), and Virology Chemistry (K.-S.Y., K.J.E., K.E.P., J.F.K.), Bristol-Myers Squibb Co., Wallingford, Connecticut
Benjamin M. Johnson
Departments of Pharmaceutical Candidate Optimization (X.Z., J.L.C., Y.W., D.M.D., X.S.H., K.W.M., M.G.S., B.M.J.), Synthesis and Analysis Technology Team (J.E.L.), and Virology Chemistry (K.-S.Y., K.J.E., K.E.P., J.F.K.), Bristol-Myers Squibb Co., Wallingford, Connecticut
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleSpecial Section on Emerging Novel Enzyme Pathways in Drug Metabolism
Phosphocholine Conjugation of HCV NS5B Inhibitors
Xiaoliang Zhuo, Joseph L. Cantone, Yingzi Wang, John E. Leet, Dieter M. Drexler, Kap-Sun Yeung, Xiaohua Stella Huang, Kyle J. Eastman, Kyle E. Parcella, Kathleen W. Mosure, Matthew G. Soars, John F. Kadow and Benjamin M. Johnson
Drug Metabolism and Disposition August 1, 2016, 44 (8) 1332-1340; DOI: https://doi.org/10.1124/dmd.115.069062
Research ArticleSpecial Section on Emerging Novel Enzyme Pathways in Drug Metabolism
Phosphocholine Conjugation of HCV NS5B Inhibitors
Xiaoliang Zhuo, Joseph L. Cantone, Yingzi Wang, John E. Leet, Dieter M. Drexler, Kap-Sun Yeung, Xiaohua Stella Huang, Kyle J. Eastman, Kyle E. Parcella, Kathleen W. Mosure, Matthew G. Soars, John F. Kadow and Benjamin M. Johnson
Drug Metabolism and Disposition August 1, 2016, 44 (8) 1332-1340; DOI: https://doi.org/10.1124/dmd.115.069062
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement